Integra LifeSciences upgraded to Neutral from Sell at BTIG

BTIG upgraded Integra LifeSciences to Neutral from Sell without a price target The stock’s valuation “has simply become so inexpensive it’s difficult to see significant downside from here,” the analyst tells investors in a research note. The firm expects near-term pressure on the shares from tax-loss selling into year-end, but the stock is “starting to appeal to deep value investors.”